Think tank for improving the supply situation

Metabolic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), can lead to serious complications. Non-invasive diagnostics and AI-supported screening have the potential to facilitate early detection in primary care. In parallel, new pharmacological therapies are on the horizon – while resmetirome has now been approved for MASH patients not only in the US but also in the EU, an extension of the indication for subcutaneous semaglutide 2.4 mg has so far been limited to the US. Lifestyle measures remain a mainstay in the treatment of MASLD/MASH.